Checkpoint Capital L.P. Has $27.20 Million Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)

Checkpoint Capital L.P. boosted its position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) by 71.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,504,307 shares of the company’s stock after buying an additional 629,307 shares during the quarter. Phathom Pharmaceuticals makes up about 13.5% of Checkpoint Capital L.P.’s holdings, making the stock its 3rd largest position. Checkpoint Capital L.P. owned about 2.20% of Phathom Pharmaceuticals worth $27,198,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the company. Huntington National Bank lifted its stake in shares of Phathom Pharmaceuticals by 62.2% during the 3rd quarter. Huntington National Bank now owns 1,471 shares of the company’s stock valued at $27,000 after buying an additional 564 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Phathom Pharmaceuticals by 41.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,470 shares of the company’s stock valued at $43,000 after acquiring an additional 722 shares during the period. US Bancorp DE lifted its position in shares of Phathom Pharmaceuticals by 28.6% during the third quarter. US Bancorp DE now owns 5,248 shares of the company’s stock worth $95,000 after acquiring an additional 1,166 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of Phathom Pharmaceuticals by 10.6% in the second quarter. The Manufacturers Life Insurance Company now owns 13,941 shares of the company’s stock worth $144,000 after acquiring an additional 1,339 shares during the period. Finally, Inspirion Wealth Advisors LLC grew its position in shares of Phathom Pharmaceuticals by 4.3% in the second quarter. Inspirion Wealth Advisors LLC now owns 36,634 shares of the company’s stock valued at $377,000 after purchasing an additional 1,500 shares in the last quarter. 99.01% of the stock is currently owned by institutional investors.

Phathom Pharmaceuticals Stock Down 0.5 %

Shares of NASDAQ PHAT opened at $8.83 on Monday. The firm has a market capitalization of $603.77 million, a P/E ratio of -1.56 and a beta of 0.72. The stock’s 50-day simple moving average is $14.68 and its two-hundred day simple moving average is $13.31. Phathom Pharmaceuticals, Inc. has a twelve month low of $6.07 and a twelve month high of $19.71.

Wall Street Analyst Weigh In

PHAT has been the topic of a number of recent research reports. Needham & Company LLC reissued a “buy” rating and set a $26.00 price objective on shares of Phathom Pharmaceuticals in a report on Friday, September 13th. HC Wainwright restated a “buy” rating and issued a $28.00 price objective on shares of Phathom Pharmaceuticals in a research report on Monday, August 12th. Finally, The Goldman Sachs Group upped their target price on shares of Phathom Pharmaceuticals from $10.00 to $12.00 and gave the stock a “neutral” rating in a report on Friday, August 9th.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.